Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis
R. Van Zyl-Smit (Cape Town, South Africa), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), C. Gessner (Leipzig, Germany)
Source: International Congress 2022 – Clinical treatment of asthma
Session: Clinical treatment of asthma
Session type: Thematic Poster
Number: 3859
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Van Zyl-Smit (Cape Town, South Africa), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), C. Gessner (Leipzig, Germany). Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis. 3859
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|